WideCells Group Plc – Named 21st Most Disruptive Company Globally in DISRUPT 100 List

2 June 2017

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce that it has been ranked as the 21st most disruptive company globally by DISRUPT 100.


The DISRUPT 100 is an annual index celebrating the businesses with the most potential to influence, change or create new global markets.  The report tracks the world’s most disruptive businesses, compiled and curated by the world’s leading entrepreneurs, investors and business people.  The list is judged by global brands including Google, Uber, Oracle, Silicon Valley Bank and Virgin StartUp, tech accelerators Microsoft Ventures, Accelerated Digital Ventures and Whitespace Ventures and entrepreneurs Emma Sinclair, Tom Goodwin and Bill Liao.  For further information please go to:


WideCells Group CEO, João Andrade, said, “This is a momentous achievement for WideCells Group.  We are delighted that our integrated stem cell support services proposition, which includes the first-of-its-kind healthcare product CellPlan, and WideAcademy, which is focused on driving education and awareness on stem cells, have been recognised as a leading force for global market change.  Via our three divisions, we are focused on making stem cell treatment affordable and accessible for families around the world.  With this in mind, the DISRUPT 100 is an index which reflects our aim as a Company: to be a pioneering force for change which drives investment and research into this innovative industry.  We believe that we are reaching a tipping point in terms of market understanding of its huge potential to treat rare and life-threatening conditions and are proud to be recognised as an intrinsic part of this medical revolution.”

For further information, please visit the Company’s website, follow us on Twitter @WideCells_Group or contact:


WideCells Group CEO – João Andrade Tel:  +351 919 033 171
Vicarage Capital Ltd Broker – Jeremy Woodgate & Rupert Williams Tel: +44 (0) 20 3651 2912
Shard Capital Partners LLP Broker – Damon Heath & Erik Woolgar Tel: +44 (0) 207 186 9950
St Brides Partners Ltd PR – Elisabeth Cowell & Charlotte Page Tel: +44 (0) 20 7236 1177


Notes to Editors


WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.  With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.


The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.


Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells
  • 82 illnesses can currently be treated using stem cell procedures
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands



This information is provided by RNS

The company news service from the London Stock Exchange